SI2423229T1 - Vezni ÄŤlen za receptor GM-CSF - Google Patents

Vezni ÄŤlen za receptor GM-CSF

Info

Publication number
SI2423229T1
SI2423229T1 SI200731285T SI200731285T SI2423229T1 SI 2423229 T1 SI2423229 T1 SI 2423229T1 SI 200731285 T SI200731285 T SI 200731285T SI 200731285 T SI200731285 T SI 200731285T SI 2423229 T1 SI2423229 T1 SI 2423229T1
Authority
SI
Slovenia
Prior art keywords
binding member
csf receptor
csf
receptor
binding
Prior art date
Application number
SI200731285T
Other languages
English (en)
Inventor
Emma Cohen
Ralph Minter
Paula Harrison
Matthew Sleeman
Andrew Nash
Louis Fabri
Original Assignee
Medimmune Limited
Zenyth Operations Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited, Zenyth Operations Pty. Ltd. filed Critical Medimmune Limited
Publication of SI2423229T1 publication Critical patent/SI2423229T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
SI200731285T 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF SI2423229T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
EP11167912.2A EP2423229B1 (en) 2006-03-27 2007-03-27 Binding member for GM-CSF receptor

Publications (1)

Publication Number Publication Date
SI2423229T1 true SI2423229T1 (sl) 2013-09-30

Family

ID=38293698

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200731100T SI1999152T1 (sl) 2006-03-27 2007-03-27 Vezni äślen za gm-csf receptor
SI200731285T SI2423229T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF
SI200731286T SI2423230T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200731100T SI1999152T1 (sl) 2006-03-27 2007-03-27 Vezni äślen za gm-csf receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731286T SI2423230T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF

Country Status (16)

Country Link
US (8) US8506960B2 (sl)
EP (3) EP2423229B1 (sl)
JP (2) JP5335662B2 (sl)
KR (2) KR101451546B1 (sl)
CN (3) CN101443360B (sl)
BR (1) BRPI0709259B1 (sl)
CA (1) CA2647449C (sl)
DK (3) DK2423230T3 (sl)
ES (3) ES2395839T3 (sl)
HK (2) HK1166988A1 (sl)
MX (2) MX2008012291A (sl)
PL (3) PL2423230T3 (sl)
PT (3) PT1999152E (sl)
RU (2) RU2495050C2 (sl)
SI (3) SI1999152T1 (sl)
WO (1) WO2007110631A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2423230T3 (pl) * 2006-03-27 2013-10-31 Medimmune Ltd Element wiążący dla receptora GM-CSF
MX2009005398A (es) 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
US8075885B2 (en) 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
ES2886063T3 (es) * 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
KR20120011883A (ko) * 2009-05-05 2012-02-08 모르포시스 아게 다발성 경화증의 치료
US20120165220A1 (en) * 2009-09-03 2012-06-28 Colgan Sean P Uses of CD116 Expression Level
AU2012322991B2 (en) * 2011-10-10 2018-02-15 Medimmune Limited Treatment for rheumatoid arthritis
KR20140103122A (ko) * 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 신경교종을 치료하기 위한 조성물 및 방법
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
PL2932264T3 (pl) * 2012-12-14 2019-09-30 Biontech Rna Pharmaceuticals Gmbh Nowe niezależne od MHC antygeny powiązane z nowotworem
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP6769879B2 (ja) 2014-05-07 2020-10-14 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
JP2017515828A (ja) * 2014-05-19 2017-06-15 メディミューン リミテッド 関節リウマチのための治療
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2017270027B2 (en) 2016-05-24 2024-07-11 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
EP3797792A1 (en) 2017-03-01 2021-03-31 MedImmune Limited Formulations of anti-gm-csfralpha monoclonal antibody
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
US20220010007A1 (en) 2018-11-09 2022-01-13 Kiniksa Pharmaeuticals, Ltd. Treatment for Giant Cell Arteritis
US20230002496A1 (en) * 2018-11-27 2023-01-05 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
JP2022535062A (ja) 2019-06-03 2022-08-04 キニクサ ファーマシューティカルズ， リミテッド Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
WO2021188409A1 (en) * 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
KR20230095983A (ko) * 2020-10-26 2023-06-29 키닉사 파마슈티컬스, 리미티드 Gm-csf 길항제를 사용한 암의 치료
EP4263597A2 (en) 2020-12-18 2023-10-25 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
ATE161883T1 (de) * 1989-08-11 1998-01-15 Amrad Corp Ltd Rezeptor für granulozyten-macrophagen- koloniestimulierungsfaktor und seine derivate
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994011404A1 (en) * 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
ES2329959T5 (es) 1998-12-10 2013-12-18 Bristol-Myers Squibb Company Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CN101824090B (zh) * 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
US7169904B2 (en) * 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
PL2423230T3 (pl) * 2006-03-27 2013-10-31 Medimmune Ltd Element wiążący dla receptora GM-CSF
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
EP2423230A1 (en) 2012-02-29
CN101443360A (zh) 2009-05-27
US20210147559A1 (en) 2021-05-20
EP1999152B1 (en) 2012-09-19
CN103641916A (zh) 2014-03-19
RU2008137763A (ru) 2010-05-10
HK1166988A1 (en) 2012-11-16
RU2012157042A (ru) 2014-07-10
SI2423230T1 (sl) 2013-09-30
EP1999152A1 (en) 2008-12-10
CN103641915A (zh) 2014-03-19
WO2007110631A1 (en) 2007-10-04
KR101481844B1 (ko) 2015-01-13
DK2423229T3 (da) 2013-08-05
US20140079708A1 (en) 2014-03-20
ES2424467T3 (es) 2013-10-02
JP5335662B2 (ja) 2013-11-06
BRPI0709259B1 (pt) 2022-05-31
US20150376285A1 (en) 2015-12-31
AU2007231128A1 (en) 2007-10-04
DK1999152T3 (da) 2013-01-14
US8506960B2 (en) 2013-08-13
RU2495050C2 (ru) 2013-10-10
US9085628B2 (en) 2015-07-21
CN101443360B (zh) 2013-11-27
SI1999152T1 (sl) 2013-02-28
PT1999152E (pt) 2013-01-07
HK1166989A1 (en) 2012-11-16
RU2639546C2 (ru) 2017-12-21
PL2423230T3 (pl) 2013-10-31
DK2423230T3 (da) 2013-08-05
PT2423230E (pt) 2013-08-26
JP5665894B2 (ja) 2015-02-04
KR20130140186A (ko) 2013-12-23
BRPI0709259A2 (pt) 2011-06-28
US20120141464A1 (en) 2012-06-07
EP2423229B1 (en) 2013-05-08
KR101451546B1 (ko) 2014-10-16
US8263075B2 (en) 2012-09-11
US20240124596A1 (en) 2024-04-18
US20190309077A1 (en) 2019-10-10
CA2647449C (en) 2017-05-16
EP2423230B1 (en) 2013-05-08
CA2647449A1 (en) 2007-10-04
ES2424468T3 (es) 2013-10-02
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
KR20080113262A (ko) 2008-12-29
PT2423229E (pt) 2013-08-22
JP2009533020A (ja) 2009-09-17
JP2013121350A (ja) 2013-06-20
MX348827B (es) 2017-06-30
CN103641915B (zh) 2017-04-12
US20190040145A1 (en) 2019-02-07
ES2395839T3 (es) 2013-02-15
US20090130093A1 (en) 2009-05-21
PL1999152T3 (pl) 2013-05-31
EP2423229A1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
SI2423229T1 (sl) Vezni ÄŤlen za receptor GM-CSF
HK1217203A1 (zh) 白介素- 的結合成員
GB2451719C (en) Binders
IL234081B (en) Antibody binds cd3–epsilon in different species
DK200800103A (en) Integreret føringskant for vindturbineblad
IL201340A (en) Antidote 3dc - epsilon in various species
EP2122511A4 (en) REST INTERFACE FOR ENTITIES
EP2114895A4 (en) TALARAZOLMETABOLITEN
GB0614727D0 (en) Solid support
EP2160336A4 (en) CONNECTION MECHANISM
EP2068017A4 (en) SLIDING MENT
HK1138281A1 (en) Minor groove binders
EP2021397A4 (en) PROCESS FOR POTENTIAL PEGYLATION
EP2108522A4 (en) BINDER
EP2007801A4 (en) BINDER FOR C-REACTIVE PROTEIN
GB2453894B (en) Binding assembly
ZA200806237B (en) Cannibinoid receptor modulators
GB0605643D0 (en) Support member
EP2088860A4 (en) COMPOUNDS FOR BINDING TO A CHEMOKINE RECEPTOR
EP1916923A4 (en) DEVICE FOR CLASSORS
HK1115660A1 (en) Mechanism for setting passage-forming-plates
GB0612891D0 (en) Disc binder
GB0603219D0 (en) Binders
GB0623399D0 (en) Receptor
GB0608516D0 (en) Receptor